
Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C), Technology (Enzyme-Linked Immunosorbent Assay, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction), End-User - Global Forecast 2024-
Description
Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C), Technology (Enzyme-Linked Immunosorbent Assay, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction), End-User - Global Forecast 2024-2030
The Hepatitis Test Solution/Diagnosis Market size was estimated at USD 3.53 billion in 2023 and expected to reach USD 3.71 billion in 2024, at a CAGR 5.48% to reach USD 5.13 billion by 2030.The hepatitis test solutions/ diagnosis are used to diagnose the hepatitis virus depending on the type of hepatitis infection. The prevalence of hepatitis is increasing, creating a need for more efficient and reliable diagnosis and testing solutions. Early detection and diagnosis of hepatitis disease are critical to successfully treat patients with improved outcomes. Thus, the vendors are focusing on developing new testing solutions that allow healthcare providers to detect the presence of the virus more accurately, allowing for better treatment outcomes and improved patient care. Moreover, government and non-profit organizations are taking necessary measures to increase awareness about hepatitis to reduce the risk by providing information about symptoms and prevention measures, encouraging regular testing, and improving access to medical facilities for diagnosis and treatment. However, high costs associated with hepatitis test solutions with the issues of inaccurate test results limit product penetration in the market. The ongoing advancements and growing penetration of point-of-care testing options are expected to augment the need for hepatitis test solutions/ diagnosis in the coming years.Regional InsightsThe hepatitis test solutions/diagnosis market in the Americas is rapidly proliferating owing to the increasing prevalence of hepatitis, ongoing awareness among the population, and advancements in testing and diagnosis procedures. As per the PAHO, there are 10,000 new hepatitis B infections each year in the Americas. The EMEA region observes an evolving hepatitis test solutions/diagnosis market due to supportive government policies to eliminate hepatitis B and C from the European economies, with the majority presence of pharmaceutical vendors making efforts to expand their hepatitis test solutions/diagnosis product portfolios. The ongoing awareness campaigns to overcome the burden of hepatitis prevalence in the Asian region and the growing presence of point-of-care testing facilities are anticipated to propel the need for hepatitis test solutions/diagnosis in the coming years.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hepatitis Test Solution/Diagnosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hepatitis Test Solution/Diagnosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hepatitis Test Solution/Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Beckman Coulter, Inc., Bio-Rad Laboratories Inc., bioMérieux SA, Cepheid, Creative Diagnostics, DiaSorin S.p.A., Epitope Diagnostics, Inc., Everlywell, Inc., F. Hoffmann-La Roche AG, FUJIREBIO Inc., GenMark Diagnostics, Inc., Grifols S.A., Hologic, Inc., Laboratory Corporation of America Holdings, MedMira Inc., Merck & Co., Inc, Meridian Bioscience, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Prometheus Laboratories, QIAGEN GmbH, Quest Diagnostics Incorporated, Randox Laboratories, Sanofi S.A., Siemens AG, Thermo Fisher Scientific Inc., Vela Diagnostics, and Werfen, S.A..
Market Segmentation & Coverage
This research report categorizes the Hepatitis Test Solution/Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:
Disease Type
Hepatitis A
Hepatitis B
Hepatitis C
Technology
Enzyme-Linked Immunosorbent Assay
Isothermal Nucleic Acid Amplification Technology
Polymerase Chain Reaction
Rapid Diagnostic Tests
End-User
Blood Banks
Diagnostic Laboratories
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Hepatitis Test Solution/Diagnosis Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hepatitis Test Solution/Diagnosis Market?
3. What are the technology trends and regulatory frameworks in the Hepatitis Test Solution/Diagnosis Market?
4. What is the market share of the leading vendors in the Hepatitis Test Solution/Diagnosis Market?
5. Which modes and strategic moves are suitable for entering the Hepatitis Test Solution/Diagnosis Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Hepatitis Test Solution/Diagnosis Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of hepatitis worldwide
- 5.1.1.2. Need for earlier detection and diagnosis of diseases
- 5.1.1.3. Increasing awareness about hepatitis by government and non-profit organizations
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with tests and diagnosis of hepatitis
- 5.1.3. Opportunities
- 5.1.3.1. Advances in viral hepatitis testing and diagnosis
- 5.1.3.2. Introduction of point-of-care testing options
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with inaccurate test results
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Hepatitis Test Solution/Diagnosis Market, by Disease Type
- 6.1. Introduction
- 6.2. Hepatitis A
- 6.3. Hepatitis B
- 6.4. Hepatitis C
- 7. Hepatitis Test Solution/Diagnosis Market, by Technology
- 7.1. Introduction
- 7.2. Enzyme-Linked Immunosorbent Assay
- 7.3. Isothermal Nucleic Acid Amplification Technology
- 7.4. Polymerase Chain Reaction
- 7.5. Rapid Diagnostic Tests
- 8. Hepatitis Test Solution/Diagnosis Market, by End-User
- 8.1. Introduction
- 8.2. Blood Banks
- 8.3. Diagnostic Laboratories
- 8.4. Hospitals
- 9. Americas Hepatitis Test Solution/Diagnosis Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Hepatitis Test Solution/Diagnosis Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Hepatitis Test Solution/Diagnosis Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Agreement, Collaboration, & Partnership
- 12.3.1.1. DOH Partners with Local Laboratories to Expand Testing for Curable Hepatitis C
- 12.3.2. New Product Launch & Enhancement
- 12.3.2.1. Sanofi Announces Launch of AVAXIM Junior in the UK for Active Immunization Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
- 12.3.2.2. Roche Launches Dual Antibody, Antigen Hepatitis C Virus Diagnostic Test
- 12.3.2.3. Abbott launches solution to detect Hepatitis B virus
- 12.3.3. Investment & Funding
- 12.3.3.1. Unitaid Makes USD 31 Million Investment in Harm Reduction Efforts to Prevent Hepatitis C Among People who Inject Drugs and Others at High Risk
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. AbbVie Inc.
- 13.1.3. Avantor Inc.
- 13.1.4. Beckman Coulter, Inc.
- 13.1.5. Bio-Rad Laboratories Inc.
- 13.1.6. bioMérieux SA
- 13.1.7. Cepheid
- 13.1.8. Creative Diagnostics
- 13.1.9. DiaSorin S.p.A.
- 13.1.10. Epitope Diagnostics, Inc.
- 13.1.11. Everlywell, Inc.
- 13.1.12. F. Hoffmann-La Roche AG
- 13.1.13. FUJIREBIO Inc.
- 13.1.14. GenMark Diagnostics, Inc.
- 13.1.15. Grifols S.A.
- 13.1.16. Hologic, Inc.
- 13.1.17. Laboratory Corporation of America Holdings
- 13.1.18. MedMira Inc.
- 13.1.19. Merck & Co., Inc
- 13.1.20. Meridian Bioscience, Inc.
- 13.1.21. OraSure Technologies, Inc.
- 13.1.22. Ortho Clinical Diagnostics
- 13.1.23. Prometheus Laboratories
- 13.1.24. QIAGEN GmbH
- 13.1.25. Quest Diagnostics Incorporated
- 13.1.26. Randox Laboratories
- 13.1.27. Sanofi S.A.
- 13.1.28. Siemens AG
- 13.1.29. Thermo Fisher Scientific Inc.
- 13.1.30. Vela Diagnostics
- 13.1.31. Werfen, S.A.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET RESEARCH PROCESS
- FIGURE 2. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2023 VS 2030
- FIGURE 3. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET DYNAMICS
- FIGURE 7. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 10. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.